Skip to main content
. Author manuscript; available in PMC: 2020 Jul 27.
Published in final edited form as: Allergy. 2020 Feb 24;75(7):1606–1617. doi: 10.1111/all.14196

FIGURE 4.

FIGURE 4

Recombinant TSLP (rTSLP) and recombinant IL-33 (rIL-33) treatment reciprocally increased IL-33 receptor (ST2) and TSLPR on lung group 2 innate lymphoid cells (ILC2). A, C, Representative histograms of ST2 and TSLPR expression on lung ILC2 from wild type (WT) mice treated with rTSLP, rIL-33 or the vehicle in an in vivo model. B, D, Mean fluorescence intensity (MFI) of ST2 and TSLPR on lung ILC2 in vivo. E, G, Representative histograms of ST2 and TSLPR expression on isolated lung ILC2 treated with rTSLP, rIL-33, rTSLP+rIL-33, or the vehicle in an in vitro model. F, H, MFI of ST2 and TSLPR on isolated lung ILC2 in vitro. The data are a combination of 2 independent experiments and shown as mean ± SD. (n=3–4). * P< 0.05.